These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33322952)

  • 21. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?
    Chaves Filho AJM; Gonçalves F; Mottin M; Andrade CH; Fonseca SNS; Macedo DS
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):213-218. PubMed ID: 33534108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug repurposing: new strategies for addressing COVID-19 outbreak.
    Shende P; Khanolkar B; Gaud RS
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):689-706. PubMed ID: 33183102
    [No Abstract]   [Full Text] [Related]  

  • 25. Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.
    Markulin I; Matasin M; Turk VE; Salković-Petrisic M
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):773-804. PubMed ID: 34982206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigational antiviral drugs for the treatment of COVID-19 patients.
    Beheshtirouy S; Khani E; Khiali S; Entezari-Maleki T
    Arch Virol; 2022 Mar; 167(3):751-805. PubMed ID: 35138438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delineating the impact of COVID-19 on antimicrobial resistance: An Indian perspective.
    Seethalakshmi PS; Charity OJ; Giakoumis T; Kiran GS; Sriskandan S; Voulvoulis N; Selvin J
    Sci Total Environ; 2022 Apr; 818():151702. PubMed ID: 34798093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19).
    Khouja T; Mitsantisuk K; Tadrous M; Suda KJ
    J Antimicrob Chemother; 2022 Apr; 77(5):1491-1499. PubMed ID: 35178565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug treatment for COVID-19.
    Ohe M; Furuya K; Goudarzi H
    Drug Discov Ther; 2021 Mar; 15(1):39-41. PubMed ID: 33612572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fighting COVID-19 with Artificial Intelligence.
    Monteleone S; Kellici TF; Southey M; Bodkin MJ; Heifetz A
    Methods Mol Biol; 2022; 2390():103-112. PubMed ID: 34731465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing Anti-Cancer Drugs for COVID-19 Treatment.
    Borcherding N; Jethava Y; Vikas P
    Drug Des Devel Ther; 2020; 14():5045-5058. PubMed ID: 33239864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exacerbation of antimicrobial resistance: another casualty of the COVID-19 pandemic?
    Razzaque MS
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):967-971. PubMed ID: 33322965
    [No Abstract]   [Full Text] [Related]  

  • 33. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation.
    Sayed AM; Khalaf AM; Abdelrahim MEA; Elgendy MO
    Int J Clin Pract; 2021 Apr; 75(4):e13877. PubMed ID: 33300221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Repurposing: An Alternative Strategy to Treat COVID-19.
    Han P; Zheng H; Wen P; Pan L; Geng D; Sun D
    Curr Pharm Biotechnol; 2022; 23(6):818-827. PubMed ID: 34250872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.
    Shirazi FM; Mirzaei R; Nakhaee S; Nejatian A; Ghafari S; Mehrpour O
    Eur J Med Res; 2022 Feb; 27(1):21. PubMed ID: 35123559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2.
    Malani M; Salunke P; Kulkarni S; Jain GK; Sheikh A; Kesharwani P; Nirmal J
    J Biomater Sci Polym Ed; 2022 Jan; 33(1):110-136. PubMed ID: 34464232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
    Sargiacomo C; Sotgia F; Lisanti MP
    Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reprogramming of antibiotics to combat antimicrobial resistance.
    Dubey KK; Indu ; Sharma M
    Arch Pharm (Weinheim); 2020 Nov; 353(11):e2000168. PubMed ID: 32776618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.
    Ulm JW; Nelson SF
    Transbound Emerg Dis; 2021 Mar; 68(2):313-317. PubMed ID: 32619318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.